Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects

Reuters

Yesterday

Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects

Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.
The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.
Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.
The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.
Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621706953"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621706953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621706953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621706953","market":"fut","top_or_hot":-1,"title":"Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        </li>\n<li>\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        </li>\n<li>\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        </li>\n<li>\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        </li>\n<li>\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        </li>\n<li>\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        </li>\n<li>\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        </li>\n<li>\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        </li>\n<li>\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLb4kZf4:1","article_id":"2621706953","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621706953","pubTimestamp":1774270822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIRA":"Mira Pharma"},"translate_title":"Mira Pharmaceuticals报告临床前研究发现Mira-55未显示THC样中枢神经系统副作用","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects\n    \n\n\n          Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.\n        \n\n          The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.\n        \n\n          Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.\n        \n\n          The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.\n        \n\n          Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603230900ACCESSWRNAPR_____1150572) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}